interleukin-2 (Interking)
✓ ApprovedShenzhen Neptunus · IL2RA · 重组蛋白
什么是 interleukin-2?
interleukin-2 是一种重组蛋白,由Shenzhen Neptunus研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。
药物档案
| 商品名 | Interking |
| 公司 | Shenzhen Neptunus |
| 药物类别 | 重组蛋白 |
| 分子靶点 | IL2RA |
| 给药途径 | Injectable (Others), Intravenous (IV), Subcutaneous Injection |
| 状态 | Approved |
作用机制
分子靶点
interleukin-2 作用于 1 个分子靶点:
| IL2RA | interleukin 2 receptor subunit alpha (IL2R, TCGFR) |
治疗适应症
interleukin-2 针对 15 个适应症,涉及 4 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adenosquamous cell lung cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Breast cancer | ✓ Approved |
| Infections and infestations | Hepatitis B | ✓ Approved |
| Infections and infestations | Leprosy | ✓ Approved |
注册免费账户还可查看另外 10 个适应症
免费注册查看全部适应症 →相关研究文献
Cerebral white matter integrity in Type-2 Diabetes Mellitus and integrated role of Interleukin-6: Findings in multiethnic middle-aged and older US-adults.
Hallab Asma A, Health and Aging Brain Study (HABS-HD) Study Team
Peripheral neural injuries, known as polyneuropathy, are largely described in patients with Type-2 Diabetes Mellitus (T 2 DM). However, less is known about the T 2 DM-associated cerebral White Matter (WM) integrity. Previous studies highlighted mediating effects of inflammation in the T 2 DM-brain association. It is, however, still unclear whether Interleukin-6 (IL-6) mediates specifically T 2 DM-cerebral WM integrity. The multiethnic ≥50-year-old study population is a subset of the Health and Aging Brain Study: Health Disparities (HABS-HD) study. Diffusion-weighted scans were analyzed, and diffusion parameters were averaged in major WM tracts. Effect sizes (Cohen's d ) were calculated after adjusting for relevant confounders. Mediation analysis was performed using 1000-fold non-parametric bootstrapping of 95% confidence intervals (CI). The results were adjusted for multiple testing using the False Discovery Rate method (FDR). Several WM tracts showed significant impairment in T 2 DM participants after adjusting for confounders and multiple testing (posterior thalamic radiation (adj. Cohen's d =0.14[0.03-024]), anterior corona radiata (adj. Cohen's d =0.15[0.04-0.26]), cingulum (adj. Cohen's d =0.14[0.03-0.25]), inferior fronto-occipital fasciculus (adj. Cohen's d =0.16[0.06-0.27]), genu of the corpus callosum (adj. Cohen's d =0.13[0.03-0.24]), and body of the corpus callosum (adj. Cohen's d =0.28[0.17-0.38])). Within two years, the effect sizes showed an increasing trend. Even in cognitively unimpaired participants, T 2 DM was associated with locally reduced WM integrity. IL-6 statistically mediated up to 15% of these major associations. The study demonstrated T 2 DM-associated impairment of intracerebral WM integrity. In T 2 DM, microstructural WM changes might start before clinically objectified cognitive impairment. The role of systemic inflammation needs to be assessed in causal frameworks.
Clinical and biomarker significance of interleukin-4 and interleukin-13 in acute exacerbations and the frequent exacerbator phenotype of chronic obstructive pulmonary disease: a systematic review.
Para Ombretta O, Raza Asim A, Carleo Christian C, Vanetti Marco M et al.
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are one of the major causes of morbidity, mortality, and hospitalization; reliable inflammatory biomarkers predicting exacerbation risk and guiding emerging interleukin (IL)-targeted therapies are still undefined. IL-4 and IL-13 are key T-helper 2 cytokines implicated in eosinophilic airway inflammation and remodeling, but their clinical and prognostic relevance in COPD is still controversial. MEDLINE and EMBASE databases were manually searched from inception to December 2025, including observational studies reporting quantitative IL-4 and/or IL-13 levels in adults with COPD and healthy controls, with measurements in serum by enzyme-linked immunosorbent assay or V-PLEX immunoassay. Study selection, data extraction, and quality assessment (Newcastle-Ottawa Scale) were performed independently by three reviewers, following PRISMA recommendations. Of 1147 records screened, 5 cohort studies (total patient number: 1168) met inclusion criteria. Across studies, serum IL-4 was consistently higher in AECOPD than in healthy controls, with IL-13 also frequently elevated during exacerbations. Comparisons between AECOPD and stable COPD yielded non-significant results. Two studies reported higher serum IL-4 in frequent versus infrequent exacerbators, whereas IL-13 was not as significantly high as IL-4. In stable COPD, IL-4 and IL-13 showed only modest, often non-significant increases versus controls. Available evidence suggests that IL-4 and IL-13 are variably upregulated in COPD, with more pronounced elevations during AECOPD and a possible association between higher IL-4 and frequent exacerbations. However, small sample sizes, methodological heterogeneity, and limited longitudinal data can't lead to definitive conclusions, requiring the need for larger, well-designed studies to validate IL-4/IL-13 as prognostic biomarkers and therapeutic targets in COPD.
Statement of Retraction: Omentin-1 alleviate interleukin-1β(IL-1β)-induced nucleus pulposus cells senescence.
Ascites-derived interleukin-10 drives tumor invasion in advanced epithelial ovarian cancer via STAT3 and ERK1/2 signaling.
Huang Yue Y, Gong Han H, Zou Kangni K, Li Bingjie B et al.
Interleukin-10 (IL-10) is a key immunoregulatory cytokine in ovarian cancer; however, its functional role and underlying mechanisms within the ascitic tumor microenvironment remain incompletely understood. We collected malignant ascites from 21 patients with advanced epithelial ovarian cancer (EOC). IL-10 concentrations were quantified using enzyme-linked immunosorbent assay. The association between ascitic IL-10 levels and clinicopathological parameters was analyzed. The effects of ascites-derived IL-10 on OC cell migration and invasion were evaluated in vitro, while in vivo experiments were conducted to assess the therapeutic potential of IL-10 neutralization. Regulatory T cells (Tregs) and M2 macrophages in ascites were characterized by flow cytometry and immunomagnetic bead sorting. IL-10 levels in malignant ascites varied markedly among patients (134.38±84.80 pg/mL) and were positively correlated with serum cancer antigen 125 levels (r=0.553, p=0.014), while no statistically significant association was observed between ascitic IL-10 levels and ascites volume (r=0.312, p=0.207). Ascites-derived IL-10 significantly promoted EOC cell migration and invasion through activation of the signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2 signaling pathways. In addition, Tregs (3.95±2.07%) and M2 macrophages (12.57±7.78%) were enriched in malignant ascites and served as important sources of IL-10, further enhancing the pro-invasive phenotype of EOC cells. Notably, IL-10 neutralization attenuated tumor progression in vivo. These findings identify IL-10 as a biologically relevant immunosuppressive mediator within the EOC ascitic microenvironment that contributes to tumor invasiveness through immune cell-tumor cell crosstalk. Targeting ascites-derived IL-10 may represent a potential microenvironment-modulating strategy for controlling malignant ascites and invasive behavior in advanced EOC.
Effectiveness and Safety of Stapokibart in Chinese Patients With Allergic Rhinitis: A Single-Center Retrospective Study.
Liang Dan D, Yang Li-Hong LH, He Xian X
Stapokibart is an anti-interleukin-4 receptor alpha subunit (IL-4Rα) monoclonal antibody, which has been approved in China for seasonal allergic rhinitis. We evaluated its effectiveness and safety in patients with allergic rhinitis in a real-world clinical setting. We conducted a single-center retrospective cohort study of adults with allergic rhinitis. Patients received subcutaneous stapokibart 300 mg (loading dose 600 mg) every 2 weeks for ≥ 4 weeks. Efficacy assessments included reflective total nasal symptom score (rTNSS), reflective total ocular symptom score (rTOSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and visual analogue scale scores for symptoms of comorbidities at week 2. The incidence of treatment-emergent adverse events (TEAEs) was also assessed. Between February 11 and May 1, 2025, 114 patients were included (median age 36 years [range 18-70]; 50.9% female), of whom 87.7% experienced type 2 inflammation-related comorbidities. At week 2, significant reductions from baseline were observed in the rTNSS (-7.0 [95% CI ‒7.4, -6.6]), rTOSS (-1.9 [95% CI ‒2.3, -1.6]), and RQLQ score (-2.3 [95% CI ‒2.5, -2.2]) (all p < 0.0001). Symptoms of type 2 inflammation-related comorbidities also improved. During stapokibart treatment, the number of concomitant medications decreased (p < 0.0001). After treatment discontinuation, 56 patients (55.4%) required no additional medication. TEAEs were reported in 8 patients (7.0%), all were mild-to-moderate. The incidence of drug-related TEAEs was 1.6%. The common TEAEs were conjunctivitis and injection site reaction. Stapokibart may be a potential treatment option for Chinese patients with improved allergic rhinitis symptoms, reduced medication use, and a favorable safety profile.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →